A Flagship VentureLabs Company

T2 Biosystems, Inc.

101 Hartwell Avenue

Lexington, MA  02421

Tel: 781.457.1200


Leadership:
John McDonough
CEO


Website:
www.t2biosystems.com


Information:
info@t2biosystems.com

T2 Biosystems, Inc.

Flagship Partners:  Harry Wilcox
Initial Investment: 
2006
Status: 
Public

T2 Biosystems (NASDAQ: TTOO) is a publicly traded in vitro diagnostics company that is using its T2 Magnetic Resonance platform, or T2MR, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, and can detect cellular targets at limits of detection as low as one colony-forming unit per milliliter, or CFU/mL. T2 Bio's initial development efforts utilizing T2MR target sepsis and hemostasis, which are areas of significant unmet medical need in which existing therapies could be more effective with improved diagnostics.

Harry Wilcox is on the Board of Directors.